DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fe4133/urological_disorde) has announced the addition of the "Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic (…)
[Read article]
[Source: Business Wire]
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new employees. The restricted stock unit awards vest as to 1/4th of the (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/60383e/thailand_pharmaceu) has announced the addition of the "Thailand Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Thailand Pharmaceuticals and Healthcare (…)
[Read article]
[Source: Business Wire]
NAARDEN, The Netherlands & MUNICH, Germany-(BUSINESS WIRE)-Forbion Capital Partners, a leading investment firm dedicated to the life science sector, today announces the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than ¬190m ($240m). (…)
[Read article]
[Source: Business Wire]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Company management will present at multiple investor conferences this month. The live webcast of each (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/886118/trends_in_generics) has announced the addition of the "Trends in Generics Industry Ownership: Evaluating Changing Industry Paradigms and Emerging Players" report to their offering. (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2745c9/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Argentina Pharmaceuticals and Healthcare (…)
[Read article]
[Source: Business Wire]
MONTREAL, CANADA-(Marketwire - September 01, 2010) - Theratechnologies (TSX: TH) announced today the appointment of Mr. John-Michel T. Huss as President and Chief Executive Officer of the Company. Mr. Huss will assume his responsibilities in the coming months. Until recently, (…)
[Read article]
[Source: BioSpace]
On August 29 at the European Cardiovascular Society Congress meeting in Stockholm, Sweden, Dr. Guillaume Paré presented new research conducted by McMaster University that in fact contradicts earlier reports that Plavix (clopidogrel) does not work in people with a certain (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/66a1b1/philippines_pharma) has announced the addition of the "Philippines Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Philippines Pharmaceuticals and (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c31cef/australia_pharmace) has announced the addition of the "Australia Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Australia Pharmaceuticals and Healthcare (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/23871e/nigeria_pharmaceut) has announced the addition of the "Nigeria Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Nigeria Pharmaceuticals and Healthcare Report (…)
[Read article]
[Source: Business Wire]
ScienceDaily (Aug. 29, 2010) New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix. See Also: Health & Medicine Stroke Prevention Heart Disease (…)
[Read article]
[Source: ScienceDaily]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d141a8/strategies_for_man) has announced the addition of the "Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of Legal, Productivity, and Quality Control (…)
[Read article]
[Source: Business Wire]
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Genzyme Corp. (NASDAQ: GENZ) today confirmed that it has received an unsolicited, non-binding proposal from Sanofi-Aventis to acquire all the outstanding shares of Genzyme for $69 per share in cash. The Genzyme board of directors met last (…)
[Read article]
[Source: Business Wire]
Wall Street Journal - Genzyme Corp. on Monday confirmed that its board had unanimously rejected an $18.5 billion all-cash offer from Sanofi-Aventis SA, raising the prospect of a hostile takeover attempt from the French pharmaceutical company.
[Read article]
[Source: BioSpace]
STOCKHOLM, SWEDEN-(Marketwire - August 30, 2010) - Portola Pharmaceuticals, Inc. today announced results from the Phase 2 INNOVATE-PCI study of its investigational antiplatelet drug, elinogrel, the only competitive, reversible direct-acting P2Y12 ADP receptor antagonist. (…)
[Read article]
[Source: BioSpace]
Experimental anti-clotting medication Brilinta (ticagrelor) works on patients, regardless of whether they had the genetic variability that has been previously shown to affect a patients' responses to Plavix (clopidogrel), Sanofi-Aventis' blockbuster medication, AztraZeneca PLC (…)
[Read article]
[Source: Medical News Today]
Sermo, the world's largest online community for physicians, announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary (…)
[Read article]
[Source: Medical News Today]
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for use of Menactra (Meningococcal [Groups (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/db0b08/type_2_diabetes) has announced the addition of GlobalData 's new report "Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017" to their offering. Type 2 Diabetes - (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/883f56/novel_antibodies_a) has announced the addition of the "Novel Antibodies and Therapeutic Proteins - Technology Challenges and Future Prospects" report to their offering. Novel (…)
[Read article]
[Source: Business Wire]
In this study, a new dynamic water vapor sorption gravimetry (DWVSG)-Raman spectroscopy coupled system is presented and described for the investigation of water (de)sorption-induced solid-phase transition of active pharmaceutical ingredients (APIs). The innovative (…)
[Read article]
[Source: NCBI PubMed]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN - News), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Genentech, a member of the Roche Group, today announced its receipt of a Refuse to File (RTF) letter (…)
[Read article]
[Source: BioSpace]
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/614240/fixed_dose_combina) has announced the addition of the "Fixed Dose Combination Products" report to their offering. Fixed dose combination (FDC) products are becoming increasingly (…)
[Read article]
[Source: Business Wire]
Bloomberg - Sanofi-Aventis SA is unwilling to pay more than $70 a share for Genzyme Corp. and may consider alternative takeover targets should the transaction fail, according to three people with knowledge of the matter.
[Read article]
[Source: BioSpace]
LONDON, Aug 26 (Reuters) - French drugmaker Sanofi-Aventis (SASY.PA) said it would continue a legal battle in the United States against a generic version of its blood clot preventer Lovenox, despite a court rebuff.
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e9e8b4/educating_the_mark) has announced the addition of the "Educating the Market: Creating Value Through Support of Continuing Medical Education 2010" report to their offering. Educating (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b5aaab/pharmaceutical_new) has announced the addition of the "Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability 2010" report to their (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4b4c71/commercial_insight) has announced the addition of the "Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales" report (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their German healthcare research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/81e154/raising_disease_st) has announced the addition of the "Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products" report to their offering. (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/54f9bf/cambodia_pharmaceu) has announced the addition of the "Cambodia Pharmaceuticals and Healthcare Report Q3 2010" report to their offering. Cambodia Pharmaceuticals and Healthcare (…)
[Read article]
[Source: Business Wire]
After a meal, insulin suppresses lipolysis through activation of its downstream kinase, Akt, resulting in inhibition of protein kinase A (PKA), the main positive effector of lipolysis. During insulin resistance, this process is ineffective, leading to a characteristic (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/504cfd/australia_pharmace) has announced the addition of the "Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape" report to (…)
[Read article]
[Source: Business Wire]
Over one-fourth of the 36 million annual outpatient prescriptions filled in the United States are known to have human genomic biomarker information available that predicts drug safety and efficacy, or both. However, to date, we have not systematically implemented strategies to (…)
[Read article]
[Source: NCBI PubMed]
The New York Times - Talks between the French pharmaceutical giant Sanofi-Aventis and the American biotech company Genzyme have hit a snag as the two sides seek to agree on a threshhold price that would allow Sanofi to proceed with due diligence, The Wall Street Journal reports.
[Read article]
[Source: BioSpace]
Wall Street Journal - WASHINGTON A federal judge held off a decision on whether to bar a generic version of Sanofi-Aventis SA's big-selling drug Lovenox, in a lengthy court hearing Tuesday that highlighted the stakes for a new generation of copycat drugs.
[Read article]
[Source: BioSpace]
The 32nd National Medicinal Chemistry Symposium, held in Minneapolis, MN, USA, included topics covering new developments in the field of medicinal chemistry. This conference report highlights selected presentations on NR2B subtype-selective NMDA receptor antagonists from Merck; (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e3c0d9/market_access_in_j) has announced the addition of Decision Resources, Inc.'s new report "Market Access in Japan: New Challenges and Opportunities for the Pharmaceutical Industry" to (…)
[Read article]
[Source: Business Wire]
LONDON, ENGLAND, 19 August 2010 Summary of unaudited results for the six months ended 30 June 2010 H1 2010 H1 2009 £m £m Results Revenue 29.3 25.5 Research and development expenses (10.0) (10.3) Operating profit 8.6 5.4 Net profit/(loss) after tax (post exceptional) 0.9 (6.1) (…)
[Read article]
[Source: BioSpace]